2019 International Congress

September 22-26, 2019. Nice, France.

View by Title View Sessions

View by Date

Monday, September 23, 2019

1:45pm-3:15pm: Clinico-genetic correlation in 102 Spinocerebellar Ataxia Type 12 (SCA 12) patients

AK. Srivastava, A. Takkar, V. Goyal, F. Mohammad, R. Rajan, A. Garg (New Delhi, India)

Ataxia · Les Muses, Level 3

1:45pm-3:15pm: Clinico-pathological Findings In Autopsy Cases With Non-Specific Glial Tauopathy

E. Zamrini, CH. Adler, GE. Serrano, N. Zhang, DR. Shprecher, SH. Mehta, MN. Sabbagh, E. Driver-Dunckley, HA. Shill, LI. Sue, TG. Beach (Sun City, AZ, USA)

Neuroanatomy · Les Muses, Level 3

1:45pm-3:15pm: Clinicopathologic Characterization and Abnormal Autophagy of HDLS

W. Tian, L. Cao, S. Chen (Shanghai, China)

Genetics · Les Muses Terrace, Level 3

1:45pm-3:15pm: Cockayne Syndrome manifesting as late adult onset cerebellar ataxia: expanding the phenotype

R. Chuang (Seattle, WA, USA)

Ataxia · Les Muses, Level 3

1:45pm-3:15pm: Comorbidities and medications in Huntington’s disease, Parkinson’s disease and the general population in a US claims database

L. Ishihara, E. Wild, D. Oliveri (Welwyn Garden City, United Kingdom)

Huntington’s Disease · Agora 3 West, Level 3

1:45pm-3:15pm: Comparison of Gene Expression in Parkinson’s Disease and Bipolar Disorder

FV. Delos Reyes (Quezon City, Philippines)

Genetics · Les Muses Terrace, Level 3

1:45pm-3:15pm: Complex disease burden in Parkinson’s and Advance Care Planning

M. Khwaja, A. Chatterjee, G. Alg, A. Cotton, L. Richardson, H. Avery (Reading, United Kingdom)

Quality of Life · Les Muses Terrace, Level 3

1:45pm-3:15pm: Complex Training of Balance in Parkinson’s Disease

ANN. Istomina, IR. Milyukhina (Saint-Petersburg, Russian Federation)

Physical and Occupational Therapy · Les Muses Terrace, Level 3

1:45pm-3:15pm: Considerations before initiating therapy in Parkinsonism: basing on the health-related quality of life.

FT. Liu, J. Wang (Shanghai, China)

Quality of Life · Les Muses Terrace, Level 3

1:45pm-3:15pm: Continuous circadian intracerebroventricular administration of anaerobic dopamine: A new therapeutic concept for Parkinson’s disease?

C. Moreau, C. Laloux, C. Lachaud, E. Pioli, Q. Li, P. Pascal, L. Defebvre, R. Bordet, E. Bezard, M. Fisichella, D. Devos (Lille, France)

Clinical Trials, Pharmacology and Treatment · Agora 3 West, Level 3